Illumina, Inc. (NASDAQ: ILMN) has introduced TruSight Oncology (TSO) Comprehensive (EU). It's a single test that evaluates several tumor genes and biomarkers to show a patient's cancer's distinct molecular profile. The in vitro diagnostic (IVD) kit will aid precision medicine decisions for cancer patients across Europe, with its global debut taking place first in Europe.

This innovative and accurate diagnostic kit offers doctors information they can utilize to match their patients to available medicines based on their tumor profile, according to clinical guidelines or clinical trials/. Moreover, Illumina is happy to be at the vanguard of bringing technologies like this to market and to be at the frontline of harnessing the genome's power for human benefit.

Furthermore, this new comprehensive genomic profiling (CGP) in vitro diagnostic (IVD) kit covers a wide range of mutations and current and emerging biomarkers associated with European Society for Medical Oncology guidelines, drug labels, and clinical trials. It increases the likelihood of discovering actionable information from each patient's biopsy. Traditional procedures, such as single biomarker tests and focused hotspot panels, have a limited number of targets to assess, increasing the risk of missing important information.

In addition, TSO Comprehensive (EU) evaluates biomarkers in 517 cancer-relevant genes across over 30 solid tumor types using DNA and RNA as well as complicated genomic signals including microsatellite instability (MSI) and tumor mutational load (TMB). This complete examination removes the need for several biopsy procedures to undertake separate, sequential gene assays.

Moreover, clinicians can make decisions on personalized medicine or clinical trial enrollment for their cancer patients in four to five days, versus weeks in some cases, thanks to the quick turnaround time of four to five days for sample-to-clinical report development. TSO Comprehensive (EU) is the first CE-marked IVD kit for CGP based on DNA and RNA content, having satisfied stringent European quality and efficacy requirements. The CE-mark is a requirement for health authorities to fund diagnostic tests, and in some European nations, it is also needed before laboratories may utilize a new testing method.